Kesimpta

Search documents
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
ZACKS· 2025-06-16 14:11
Industry Overview - The Zacks Large Cap Pharmaceuticals industry includes major global companies developing multi-million-dollar drugs across various therapeutic areas such as neuroscience, cardiovascular, metabolism, rare diseases, immunology, and oncology [4] - Continuous innovation and significant investment in R&D are defining characteristics of these companies, with regular mergers and acquisitions being common [4][5] Current Market Conditions - The industry has shown resilience amid broader macroeconomic uncertainties, with a year-to-date performance increase of 3.9%, outperforming the Zacks Medical Sector's decline of 1.5% and the S&P 500's rise of 1.7% [14] - The current forward 12-month price-to-earnings (P/E) ratio for the industry is 15.65X, lower than the S&P 500's 21.89X and the Zacks Medical Sector's 19.31X, indicating potential value [17] Key Players and Performance - **Bayer**: Key drugs like Nubeqa and Kerendia are driving growth, with plans for new drug launches in 2025. The stock has risen 61.9% year-to-date, with 2025 EPS estimates increasing from $1.19 to $1.25 [20][22] - **Pfizer**: Strengthened its oncology position with the acquisition of Seagen. Despite challenges from declining COVID-19 product sales and patent expirations, non-COVID operational revenues are improving. The stock has lost 4.2% year-to-date, but 2025 EPS estimates have risen from $2.98 to $3.06 [25][26][28] - **Novartis**: Following the separation of Sandoz, it has a strong portfolio with drugs like Kisqali and Leqvio. The stock has risen 25.6% year-to-date, with 2025 EPS estimates increasing from $8.46 to $8.74 [31][32] - **AbbVie**: Successfully transitioned from the loss of exclusivity of Humira with new drugs like Skyrizi and Rinvoq. The stock has risen 9.5% year-to-date, with stable 2025 EPS estimates at $12.28 [35][37] - **Sanofi**: Dupixent is a key growth driver, supported by a strong vaccine portfolio. The stock has risen 6.3% year-to-date, with 2025 EPS estimates increasing from $4.43 to $4.56 [40][42] M&A and Innovation Trends - The industry is characterized by aggressive M&A activity, with large pharmaceutical companies acquiring innovative small and mid-cap biotech firms to enhance their pipelines [6][7] - Recent notable M&A activity includes Sanofi's offer to acquire Blueprint Medicines for approximately $9.5 billion, indicating continued robust M&A activity expected throughout the year [8]
Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
Globenewswire· 2025-05-28 10:15
Core Insights - Alvotech and Advanz Pharma have expanded their commercial partnership to include three additional biosimilar candidates, enhancing their collaboration in the European market [1][2][8] Group 1: Partnership Details - The new agreement includes biosimilar candidates to Ilaris® (canakinumab) and Kesimpta® (ofatumumab), along with a third undisclosed candidate, with Alvotech responsible for development and supply, while Advanz Pharma handles registration and commercialization in Europe [2][4] - The agreement encompasses development and commercial milestones totaling up to US$180 million (EUR 160 million) and includes a revenue-sharing model between the partners [2][4] Group 2: Market Potential - The partnership now covers proposed biosimilars referencing over ten originator biologics, with the current addressable market for these products in the relevant countries estimated at least US$13.8 billion [5][3] - Advanz Pharma aims to broaden access to rare disease and specialty medicines through this expanded collaboration, reinforcing its growth strategy in the biosimilars sector [4][3] Group 3: Company Background - Alvotech is focused on developing and manufacturing biosimilar medicines, with a pipeline that includes eight disclosed candidates targeting various diseases, including autoimmune disorders and cancer [7] - Advanz Pharma operates globally, with a focus on specialty, hospital, and rare disease medicines, and has a commercial presence in over 90 countries [10]
Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology
Seeking Alpha· 2025-05-19 11:03
Core Insights - Genmab A/S is a biotech innovator focusing on antibody engineering and has a strategy that includes direct commercialization of its products Tivdak and Epcoritamab, as well as monetizing through partnerships and licensing drugs like Darzalex and Kesimpta [1] Group 1 - The company retains its value through innovative antibody engineering [1] - Genmab's strategy involves both direct product sales and partnerships for drug monetization [1]
Genmab Announces Financial Results for the First Quarter of 2024
Globenewswire· 2025-05-08 15:01
May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL)Rinatabart sesutecan (Rina-S®) continues to show encouraging antitumor activity in patients with advanced ovarian cancer in data presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer® (SGO) Tivd ...
诺华制药(NVS.US)Q1业绩超预期 上调全年增长目标
智通财经网· 2025-04-29 07:03
Group 1: Financial Performance - Novartis reported Q1 net sales of $13.2 billion, a 15% year-over-year increase, exceeding analyst expectations of $13.12 billion [1] - Adjusted core operating profit reached $5.58 billion, a 27% increase, significantly above the market expectation of $5.07 billion [1] - The company raised its 2025 full-year net sales growth forecast from mid-single digits to high-single digits, and core operating profit growth from high-single digits to low double digits [1] Group 2: Product Performance - The growth in sales was primarily driven by the heart failure treatment drug Entresto and the arthritis drug Cosentyx [1] - There is a notable increase in market demand for breast cancer treatment drug Kisqali, multiple sclerosis drug Kesimpta, and cholesterol-lowering drug Leqvio [1][2] Group 3: Strategic Initiatives - Facing pressure from generic drug competition, Novartis is accelerating its focus on innovative therapies [2] - The company plans to invest $23 billion in the U.S. over the next five years to establish and expand 10 production sites, ensuring local production of key drugs for the U.S. market [3] - Novartis emphasizes its strategic focus on key markets including the U.S., China, Germany, and Japan [3]
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Globenewswire· 2025-04-29 05:00
Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali (+56% cc), Kesimpta (+43% cc), Cosentyx (+18% cc), Leqvio (+72% cc) and Scemblix (+76% cc) Core operating income margin1 reached 42.1%, +400 basis points (cc), mainly driven by higher net sales Operating income grew +44% (cc, +38% USD); net income up +37% (cc, +34% USD)Core EPS1 grew +31% (cc, ...